The PI3K/Akt inhibitor LY294002 reverses BCRP-mediated drug resistance without affecting BCRP translocation

Oncology Reports

Volumn 27, Issue 6, 2012, Pages 1703-1709

  Imai, Yasuo ^a   Yoshimori, Mayumi ^a   Fukuda, Kazunori ^a   Yamagishi, Hidetsugu ^a   Ueda, Yoshihiko ^a  

^a DOKKYO MEDICAL UNIVERSITY   (Japan)

Author keywords

Breast cancer resistance protein; Drug resistance; LY294002; PI3K Akt

Indexed keywords

2 MORPHOLINO 8 PHENYLCHROMONE; BREAST CANCER RESISTANCE PROTEIN; FIRTECAN; PHOSPHATIDYLINOSITOL 3 KINASE; PROTEIN KINASE B; WORTMANNIN;

ARTICLE; CANCER RESISTANCE; CELL STRAIN MCF 7; CELL SURFACE; COMPETITIVE INHIBITION; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG EFFECT; DRUG EFFICACY; DRUG MECHANISM; DRUG POTENTIATION; DRUG STRUCTURE; FLOW CYTOMETRY; FLUORESCENCE ACTIVATED CELL SORTING; HUMAN; HUMAN CELL; IMMUNOFLUORESCENCE; IMMUNOHISTOCHEMISTRY; PRIORITY JOURNAL; PROTEIN DETERMINATION; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN LOCALIZATION; PROTEIN TRANSPORT; SIGNAL TRANSDUCTION; WESTERN BLOTTING;

ANDROSTADIENES; ANTINEOPLASTIC AGENTS; ATP-BINDING CASSETTE TRANSPORTERS; BIOLOGICAL TRANSPORT; BREAST NEOPLASMS; CAMPTOTHECIN; CELL LINE, TUMOR; CELL PROLIFERATION; CHROMONES; DRUG RESISTANCE, MULTIPLE; DRUG RESISTANCE, NEOPLASM; ENZYME INHIBITORS; HUMANS; MORPHOLINES; NEOPLASM PROTEINS; PHOSPHATIDYLINOSITOL 3-KINASES; PROTEIN TRANSPORT; PROTO-ONCOGENE PROTEINS C-AKT; TOPOTECAN;

EID: 84860752480     PISSN: 1021335X     EISSN: 17912431     Source Type: Journal    
DOI: 10.3892/or.2012.1724     Document Type: Article

References (33)

1. Bates SE, Robey R, Miyake K, Rao K, Ross DD and Litman T: The role of half-transporters in multidrug resistance. J Bioenerg Biomembr 33: 503-511, 2001. (Pubitemid 34052576)
2. Stavrovskaya AA: Cellular mechanisms of multidrug resistance of tumor cells. Biochemistry 65: 95-106, 2000.
3. Gottesman MM, Fojo T and Bates SE: Multidrug resistance in cancer: role of ATP-dependent transporters. Nat Rev Cancer 2: 48-58, 2002. (Pubitemid 37328807)
4. Ng SSW, Tsao MS, Chow S and Hedley DW: Inhibition of phosphatidylinositide 3-kinase enhances gemcitabine-induced apoptosis in human pancreatic cancer cells. Cancer Res 60: 5451-5455, 2000.
5. Ding S, Chamberlain M, McLaren A, Goh L, Duncan I and Wolf CR: Cross-talk between signalling pathways and the multidrug resistant protein MDR-1. Br J Cancer 85: 1175-1184, 2001. (Pubitemid 33052318)
6. Hu L, Hofmann J, Lu Y, Mills GB and Jaffe RB: Inhibition of phosphatidylinositol 3′-kinase increases efficacy of paclitaxel in in vitro and in vivo ovarian cancer models. Cancer Res 62: 1087-1092, 2002. (Pubitemid 34160292)
7. Clark AS, West K, Streicher S and Dennis PA: Constitutive and inducible Akt activity promotes resistance to chemotherapy, trastuzumab, or tamoxifen in breast cancer cells. Mol Cancer Ther 1: 707-717, 2002.
8. Jin W, Wu L, Liang K, Liu B, Lu Y and Fan Z: Roles of the PI-3K and MEK pathways in Ras-mediated chemoresistance in breast cancer cells. Br J Cancer 89: 185-191, 2003. (Pubitemid 36897956)
9. Allikmets R, Schriml L, Hutchinson A, Romano-Spica V and Dean M: A human placenta-specific ATP-binding cassette gene (ABCP) on chromosome 4q22 that is involved in multidrug resistance. Cancer Res 58: 5337-5339, 1998. (Pubitemid 28551112)
10. Doyle LA, Yang W, Abruzzo LV, Krogmann T, Gao Y, Rishi AK and Ross DD: A multidrug resistance transporter from human MCF-7 breast cancer cells. Proc Natl Acad Sci USA 95: 15665-15670, 1998. (Pubitemid 29018757)
11. Miyake K, Mickley L, Litman T, et al: Molecular cloning of cDNAs which are highly overexpressed in mitoxantrone-resistant cells: demonstration of homology to ABC transport genes. Cancer Res 59: 8-13, 1999. (Pubitemid 29062946)
12. Jonker JW, Buitelaar M, Wagenaar E, et al: The breast cancer resistance protein protects against a major chlorophyll-derived dietary phototoxin and protoporphyria. Proc Natl Acad Sci USA 99: 15649-15654, 2002. (Pubitemid 35403986)
13. van Herwaarden AE, Jonker JW, Wagenaar E, Brinkhuis RF, Schellens JH, Beijnen JH and Schinkel AH: The breast cancer resistance protein (Bcrp1/Abcg2) restricts exposure to the dietary carcinogen 2-amino-1-methyl-6-phenylimidazo[4, 5-b]pyridine. Cancer Res 63: 6447-6452, 2003. (Pubitemid 37255195)
14. Imai Y, Asada S, Tsukahara S, Ishikawa E, Tsuruo T and Sugimoto Y: Breast cancer resistance protein exports sulfated estrogens but not free estrogens. Mol Pharmacol 64: 610-618, 2003. (Pubitemid 37048564)
15. Suzuki M, Suzuki H, Sugimoto Y and Sugiyama Y: ABCG2 transports sulfated conjugates of steroids and xenobiotics. J Biol Chem 278: 22644-22649, 2003. (Pubitemid 36830322)
16. Zhou S, Schuetz JD, Bunting KD, et al: The ABC transporter Bcrp1/ABCG2 is expressed in a wide variety of stem cells and is a molecular determinant of the side-population phenotype. Nat Med 7: 1028-1034, 2001. (Pubitemid 32937383)
17. Maliepaard M, van Gastelen MA, de Jong LA, et al: Overexpression of the BCRP/MXR/ABCP gene in a topotecan-selected ovarian tumor cell line. Cancer Res 59: 4559-4563, 1999. (Pubitemid 29428958)
18. Kawabata S, Oka M, Shiozawa K, et al: Breast cancer resistance protein directly confers SN-38 resistance of lung cancer cells. Biochem Biophys Res Commun 280: 1216-1223, 2001. (Pubitemid 32917772)
19. Yanase K, Tsukahara S, Asada S, Ishikawa E, Imai Y and Sugimoto Y: Gefitinib reverses breast cancer resistance protein-mediated drug resistance. Mol Cancer Ther 3: 1119-1125, 2004. (Pubitemid 39295009)
20. Mogi M, Yang J, Lambert JF, et al: Akt signaling regulates side population cell phenotype via Bcrp translocation. J Biol Chem 278: 39068-39075, 2003. (Pubitemid 37221810)
21. Takada T, Suzuki H, Gotoh Y and Sugiyama Y: Regulation of the cell surface expression of human BCRP/ABCG2 by the phosphorylation state of Akt in polarized cells. Drug Meta Dispos 33: 905-909, 2005. (Pubitemid 41002770)
22. Bleau AM, Hambardzumyan D, Ozawa T, Fomchenko EI, Huse JT, Brennan CW and Holland EC: PTEN/PI3K/Akt pathway regulates the side population phenotype and ABCG2 activity in glioma tumor stem-like cells. Cell Stem Cell 4: 226-235, 2009.
23. Imai Y, Ishikawa E, Asada S and Sugimoto Y: Estrogen-mediated post transcriptional down-regulation of beast cancer resistant protein/ABCG2. Cancer Res 65: 596-604, 2005.
24. Kono T, Imai Y, Yasuda S, et al: The CD155/poliovirus receptor enhances the proliferation of ras-mutated cells. Int J Cancer 122: 317-324, 2008. (Pubitemid 350234717)
25. Imai Y, Tsukahara S, Ishikawa E, Tsuruo T and Sugimoto Y: Estrone and 17β-estradiol reverse breast cancer resistance protein-mediated multidrug resistance. Jpn J Cancer Res 93: 231-235, 2002. (Pubitemid 34464356)
26. Armstrong L, Hughes O, Yung S, et al: The role of PI3K/AKT, MAPK/ERK and NFkappabeta signalling in the maintenance of human embryonic stem cell pluripotency and viability highlighted by transcriptional profiling and functional analysis. Hum Mol Genet 15: 1894-1913, 2006. (Pubitemid 43821780)
27. Wieman HL, Wofford JA and Rathmell JC: Cytokine stimulation promotes glucose uptake via phosphatidylinositol-3 kinase/Akt regulation of Glut1 activity and trafficking. Mol Biol Cell 18: 1437-1446, 2007. (Pubitemid 46626638)
28. Edinger AL and Thompson CB: Akt maintains cell size and survival by increasing mTOR-dependent nutrient uptake. Mol Biol Cell 13: 2276-2288, 2002. (Pubitemid 34831333)
29. Imai Y, Ohmori K, Yasuda S, Wada M, Suzuki T, Fukuda K and Ueda Y: Breast cancer resistance protein/ABCG2 is differentially regulated downstream of extracellular signal-regulated kinase. Cancer Sci 100: 1118-1127, 2009.
30. Srivastava AK: Inhibition of phosphorylase kinase, and tyrosine protein kinase activities by quercetin. Biochem Biophys Res Commun 131: 1-5, 1985.
31. Agullo G, Gamet-Payrastre L, Manenti S, Viala C, Rémésy C, Chap H and Payrastre B: Relationship between flavonoid structure and inhibition of phosphatidylinositol 3-kinase: a comparison with tyrosine kinase and protein kinase C inhibition. Biochem Pharmacol 53: 1649-1657, 1997. (Pubitemid 27356094)
32. Imai Y, Tsukahara S, Asada S and Sugimoto Y: Phytoestrogens/flavonoids reverse breast cancer resistance protein/ABCG2-mediated multidrug resistance. Cancer Res 64: 4346-4352, 2004. (Pubitemid 38802442)
33. Abdul-Ghani R, Serra V, Györffy B, Jürchott K, Solf A and Schäfer R: The PI3K inhibitor LY294002 blocks drug export from resistant colon carcinoma cells overexpressing MRP1. Oncogene 25: 1743-1752, 2006.